Market Research Logo

House Dust Mite Allergy - Pipeline Review, H2 2015

House Dust Mite Allergy - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘House Dust Mite Allergy - Pipeline Review, H2 2015’, provides an overview of the House Dust Mite Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for House Dust Mite Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for House Dust Mite Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for House Dust Mite Allergy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the House Dust Mite Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the House Dust Mite Allergy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy Overview
Therapeutics Development
Pipeline Products for House Dust Mite Allergy - Overview
Pipeline Products for House Dust Mite Allergy - Comparative Analysis
House Dust Mite Allergy - Therapeutics under Development by Companies
House Dust Mite Allergy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
House Dust Mite Allergy - Products under Development by Companies
House Dust Mite Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Anergis SA
Biomay AG
Circassia Pharmaceuticals Plc
DBV Technologies S.A.
HAL Allergy BV
Stallergenes S.A.
House Dust Mite Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AllerDM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for House Dust Mite Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BM-35 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-8237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STG-320 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Allergic Rhino-Conjunctivitis and House Dust Mite Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
House Dust Mite Allergy - Recent Pipeline Updates
House Dust Mite Allergy - Dormant Projects
House Dust Mite Allergy - Discontinued Products
House Dust Mite Allergy - Product Development Milestones
Featured News & Press Releases
Jun 09, 2015: ALK’s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
Jun 04, 2015: ALK announces top-line results from its partner MSD's North American Phase III trial of house dust mite SLIT-tablet
Jun 16, 2014: ALK's Partner for Japan Announces Trial Results for House Dust Mite SLIT-Tablet
Mar 20, 2014: ALK's Partner Merck Initiates Phase III Clinical Development Programme in North America with the New Allergy Immunotherapy Tablet
Mar 20, 2014: House dust mite SLIT-tablet enters Phase III clinical development
Mar 04, 2014: Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet
Sep 12, 2013: Circassia's house dust mite allergy treatment achieves long-term symptom reduction
Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma
Jun 19, 2013: Anergis Files Provisional US Patent On AllerDM Dust Mite Allergy Treatment
Jun 19, 2013: ALK-Abello's New Allergy Immunotherapy Tablet Meets Primary Endpoint In Pivotal Phase III Trial In Patients With House Dust Mite Allergy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for House Dust Mite Allergy, H2 2015
Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H2 2015
House Dust Mite Allergy - Pipeline by Anergis SA, H2 2015
House Dust Mite Allergy - Pipeline by Biomay AG, H2 2015
House Dust Mite Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2015
House Dust Mite Allergy - Pipeline by DBV Technologies S.A., H2 2015
House Dust Mite Allergy - Pipeline by HAL Allergy BV, H2 2015
House Dust Mite Allergy - Pipeline by Stallergenes S.A., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
House Dust Mite Allergy Therapeutics - Recent Pipeline Updates, H2 2015
House Dust Mite Allergy - Dormant Projects, H2 2015
House Dust Mite Allergy - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for House Dust Mite Allergy, H2 2015
Number of Products under Development for House Dust Mite Allergy - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report